Phil Polakoff who has been engaged in the healthcare field for over 35 years, offers a unique perspective on where we are and where we are going. Brett Johnson: Phil, what do you see as the biggest challenges in health and the delivery of healthcare in the U.S.A and worldwide? Phil Polakoff: It’s quite complex. Health and healthcare are not defined as the same. Health is the state of complete physical, mental and social well being and not merely the absence of disease and infirmity, and healthcare goes on to the issue of illness and infirmity. As such, it’s how…
Author: onemednews_zxrtna
Company Successfully Transfers T-Cell Receptor Genetic Material into Human Hematopoietic Stem Cells ImmunoCellular Therapeutics, Ltd., a Los Angeles-based clinical stage immuno-oncology company, has achieved an important milestone toward initiating pre-clinical trials of its Stem-to-T-Cell approach to cancer therapy. ImmunoCellular Therapeutics has verified the successful transfer of selected T-cell receptor genetic material into human hematopoietic stem cells. This milestone is a key component of the ongoing proof-of-concept work that ImmunoCellular Therapeutics is conducting for its Stem-to-T-Cell technology. Steven J. Swanson, PhD, ImmunoCellular Therapeutics’ Senior Vice President of Research, stated, “We are excited to have achieved this critical next milestone in our…
TRE-515 Therapy Targets Multiple Pathways to Improve Treatment Efficacy Over Single-Agent Approaches Trethera Corporation, a Los Angeles-based clinical-stage biopharmaceutical company, is developing cancer treatments for orphan blood cancers with high unmet needs. Trethera’s lead program combines TRE-515, a novel deoxycytidine kinase inhibitor, with de novo pathway inhibitors. TRE-515 has been chemically engineered to improve bioavailability and demonstrates robust anti-tumor activity in combination therapies. By targeting multiple pathways using rationally-designed combinations of drugs, Trethera’s therapeutic approaches may improve treatment efficacy and overcome the limitations of single-agent therapies. The dual blockade of nucleotide synthesis may additionally minimize the development of drug resistance.…
Targeted DiversiTy™ Therapy Promotes Surveillance and Destruction of Cancer Cells By Re-Educating Patients’ Own T Cells Geneius is an immuno-oncology company based in Natick, MA, that is focused on T-cell immunotherapies for cancer and infections. Geneius has developed an innovative autologous, adoptive T-cell therapy technology (Targeted DiversiTy™) that promotes surveillance and destruction of cancer cells by the immune system. Geneius’ Targeted DiversiTy™ therapy re-educates patients’ own T cells to be responsive to multiple previously muted tumor antigens, resulting in a stronger and more durable immune response that is less susceptible to immune evasion. Targeted DiversiTy™ is an alternative approach to…
Light-Activated Intracellular Acidosis Therapy May Cause Cancer Cells to Undergo Rapid Apoptosis Vitanova Biomedical Inc., a San Antonio-based early-stage biotechnology company, is currently conducting pre-clinical trials on a proprietary Light-Activated Intracellular Acidosis therapy that potentially kills multiple types of aggressive cancer cells. Vitanova Biomedical is working with clinical research organization partner Cancer Insight, also based in San Antonio, to conduct its Phase I through Phase III clinical trials. Light-Activated Intracellular Acidosis, Vitanova Biomedical’s proprietary technology platform, utilizes photodynamic therapy as a therapeutic treatment. A photosensitizing agent, o-nitrobenzaldehyde (o-NBA), is injected into cancer cells and exposed to a specific wavelength of…
Immix Therapies Enhance Apoptotic Activity of FDA-Approved Agents by 5X and Catalyze Total Shift in Tumor Micro-Environment Immix Biopharma, Inc., a Los Angeles-based clinical-stage biopharmeceutical company developing therapies for high unmet medical needs, has recently appointed two world-reknowned oncologists to its Medical Advisory Board. Dr. George Sledge is Professor and Chief of the Division of Oncology at Stanford University Medical Center. Dr. Razelle Kurzrock is Professor and Chief of the Division of Hematology & Oncology at UCSD Moores Cancer Center. Both Drs. Sledge and Kurzrock will provide Immix Biopharma with strategic guidance and insights on critical unmet areas of need…
Blood-Filtering Device Treats Cancer By Removing Blocking Proteins Released By Cancer Cells Immunicom Inc., a San Diego-based immuno-oncology company, is developing a proprietary subtractive device-based technology platform as a novel approach to treating cancer. Immunicom’s immunotherapy platform (Immunopheresis™) potentially treats all cancer types and other terminal diseases through a blood-filtering device that removes “blocking proteins” released by cancer cells. The absence of blocking proteins in blood restores the immune system, better enabing it to naturally fight cancer. Immunicom’s immunomodulatory technologies incorporate an extracorporeal, medical device-based “subtractive” approach utilizing its proprietary apheresis column. The lead therapy currently under development focuses on…
Initiated by a global think tank, Klosters Institute, the objective is to create a consortium committed to fostering collaboration. Research to assessing connectivity the global cancer ecosystem and published in a Cancer Impact Guide targeted at family offices, foundations and impact investors. Initiated by a global think tank, Klosters Institute, the objective is to create a consortium committed to fostering collaboration and initially presented at the New York Oncology Conference May 8 and 9 Conference will feature a global update on progress in oncology highly screened group of companies and key opinion leaders in the field of oncology. Commissioned by…